Trial Profile
A Phase I Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Dasatinib (Primary) ; Temsirolimus (Primary)
- Indications Brain cancer; Glioma; Solid tumours
- Focus Adverse reactions
- 27 Feb 2024 Planned End Date changed from 31 Oct 2023 to 31 Oct 2024.
- 27 Feb 2024 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2024.
- 01 Sep 2023 Planned End Date changed from 31 Oct 2022 to 31 Oct 2023.